Future prospects of anticytokine therapy in chronic heart failure (Q36087238)

12 August 2017

1 reference

title

Future prospects of anticytokine therapy in chronic heart failure (English)

1 reference

12 August 2017

1 reference

chronic heart failure

1 reference

1

Stephan von Haehling

1 reference

12 August 2017

2

Stefan D Anker

1 reference

PubMed ID

15806710

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

2

1 reference

12 August 2017

163-176

1 reference

Inflammatory mediators in chronic heart failure: an overview

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Recent insights into the role of tumor necrosis factor in the failing heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

The p70 tumor necrosis factor receptor mediates cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Basic mechanisms in heart failure: the cytokine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Increased circulating cytokines in patients with myocarditis and cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Cytokine-binding proteins: stimulating antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

A CD14-independent LPS receptor cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

The relationship between cholesterol and survival in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

The endotoxin-lipoprotein hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Novel therapies for sepsis: antiendotoxin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Statins and the role of nitric oxide in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Subcellular localization and characterization of nitric oxide synthase(s) in endothelial cells: physiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Inhibition of endogenous TNF formation by pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Cachexia: a therapeutic approach beyond cytokine antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effect of thalidomide in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Growth hormone resistance in chronic heart failure and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

Immunosuppressive effects of apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.2.163

10.1517/13543784.14.2.163

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15806710